

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECURITY AGREEMENT

CONVEYING PARTY DATA

Name	Execution Date
GE BUSINESS FINANCIAL SERVICES, INC.	09/28/2010

RECEIVING PARTY DATA

Name:	PRESTWICK PHARMACEUTICALS, INC.
Street Address:	700 ROUTE 202/206 NORTH
City:	BRIDGEWATER
State/Country:	NEW JERSEY
Postal Code:	08801

PROPERTY NUMBERS Total: 3

Property Type	Number
Application Number:	10524869
Application Number:	10486925
Application Number:	10524693

CORRESPONDENCE DATA

Fax Number: (866)826-5420
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
 Phone: 3016380511
 Email: ipresearchplus@comcast.net
 Correspondent Name: IP Research Plus, Inc.
 Address Line 1: 21 Tadcaster Circle
 Address Line 2: Attn: Penelope J.A. Agodoa
 Address Line 4: Waldorf, MARYLAND 20602

ATTORNEY DOCKET NUMBER:	36144
NAME OF SUBMITTER:	Penelope J.A. Agodoa

Total Attachments: 4
 source=36144#page1.tif

OP \$120.00 10524869

501312938

**PATENT
 REEL: 025102 FRAME: 0710**

source=36144#page2.tif
source=36144#page3.tif
source=36144#page4.tif

RECORDATION FORM COVER SHEET PATENTS ONLY

To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

1. Name of conveying party(ies)

GE BUSINESS FINANCIAL SERVICES, INC.

Additional name(s) of conveying party(ies) attached? Yes No

2. Name and address of receiving party(ies)

Name: PRESTWICK PHARMACEUTICALS, INC.

Internal Address: _____

Street Address: 700 ROUTE 202/206 NORTH

City: BRIDGEWATER

State: NEW JERSEY

Country: USA Zip: 08801

Additional name(s) & address(es) attached? Yes No

3. Nature of conveyance/Execution Date(s):

Execution Date(s) SEPTEMBER 28, 2010

- Assignment Merger
- Security Agreement Change of Name
- Joint Research Agreement
- Government Interest Assignment
- Executive Order 9424, Confirmatory License
- Other RELEASE OF SECURITY AGREEMENT

4. Application or patent number(s):

This document is being filed together with a new application.

A. Patent Application No.(s)

PLEASE SEE ATTACHED SCHEDULE.

B. Patent No.(s)

PLEASE SEE ATTACHED SCHEDULE.

Additional numbers attached? Yes No

5. Name and address to whom correspondence concerning document should be mailed:

Name: IP Research Plus

Internal Address: _____

Attn: Penelope J.A. Agodoa

Street Address: _____

21 Tadcaster Circle

City: Waldorf

State: MD

Zip: 20602

Phone Number: 301-638-0511

Fax Number: 866-826-5420

Email Address: orders@ipresearchplus.com

6. Total number of applications and patents involved: 3**7. Total fee (37 CFR 1.21(h) & 3.41) \$** _____

- Authorized to be charged by credit card
- Authorized to be charged to deposit account
- Enclosed
- None required (government interest not affecting title)

8. Payment Information

a. Credit Card Last 4 Numbers _____
Expiration Date _____

b. Deposit Account Number _____
Authorized User Name _____

9. Signature:

Signature

Date

ERIC SPIERER
Name of Person Signing

Total number of pages including cover sheet, attachments, and documents:

4

RELEASE OF PATENT SECURITY INTEREST,
dated as of September 28, 2010 (this "Release"), by PRESTWICK
PHARMACEUTICALS, INC. (as defined below). Capitalized terms
used herein and not otherwise defined shall have the meanings
assigned to such terms in the Credit Agreement referred to below.

Reference is made to (i) the Credit and Security Agreement, dated as of June 27, 2007 (the "Credit Agreement"), among Prestwick Pharmaceuticals, Inc., a Delaware Corporation ("Grantor"), GE Business Financial Services, formerly known as Merrill Lynch Business Financial Services, Inc. ("Lender") and (ii) all guaranties, security agreements, mortgages, subordination agreements, intercreditor agreements, pledge agreements, blocked account agreements, notes and other documents and instruments relating thereto (together with the Credit Agreement, collectively, the "Credit Documents") as referenced in the Payoff Letter ("Payoff Letter"), dated September 15, 2008, between the Grantor and the Lender.

WHEREAS, pursuant to the Credit Documents, the Grantor granted a security interest to the Lender in, among other things, the patents of the Grantor set forth on Schedule I hereto (the "Patents"), which security interest was recorded with the United States Patent & Trademark Office (the "USTPO") on July 31, 2007 at 019605/0664.

WHEREAS, in connection with the termination of the Obligations under the Credit Documents and the payment in full of all of the Obligations, and the release of security interests under the Credit Documents, the Grantor has informed the Lender of its desire to obtain the release of all right, title and interest of the Lender, the Secured Parties and each other grantee or beneficiary in and to the Patents granted under the Credit Documents.

NOW, THEREFORE, in exchange for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Lender does hereby release, cancel, relinquish and discharge any and all security interests it has against the Patents and reassigns all right, title and interest it has in the Patents to the Grantor. The Lender agrees to take all reasonable steps to evidence the release and termination of the Lender's security interests in the Patents and provide to the Grantor, assigns or other legal representatives all such reasonable cooperation and assistance, as reasonably requested by the Grantor and at the expense of the Grantor, to more fully and effectively effectuate the purposes of this Release.

THIS RELEASE SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK AND SHALL BE BINDING UPON THE PARTIES HERETO AND THEIR RESPECTIVE SUCCESSORS AND ASSIGNS.

IN WITNESS WHEREOF, the Grantor has duly executed this Release as of the day and year first above written.

GE BUSINESS FINANCIAL
SERVICES, INC.

By: 

Name: Peter Gibson

Title: Its Duly Authorized Signator,

[Signature Page to Prestwick Patent Release]

Schedule I

UNITED STATES PATENTS

Case Reference	Internal Title	Country	Filing Date	Filing Number	Grant Date	Grant Number	Expiration Date	Current Status	Registered Owner
P149-US-PCT	DERIVATIVES OF GLYCINERGIC R(+)-2-AMINO-3-HYDROXYPROPAN OIC ACID	United States Of America	01 Aug 2003	10/524,869	10 Feb 2009	7488755	08 Feb 2025	Granted	PRESTWICK PHARMACEUTICALS, INC.
P150-US-PCT	NOVEL PIPERIDIN-2,6-DIONE BISULPHATE SALTS AND THEIR USE FOR THE TREATMENT OF STRESS-RELATED AFFECTIVE DISORDERS	United States Of America	22 Aug 2002	10/486925	13 Mar 2007	7189742	22 Aug 2022	Granted	PRESTWICK PHARMACEUTICALS, INC.
P151-US-PCT	PIPERIDIN-2,6-DIONE PAMOATE SALTS AND THEIR USE FOR THE TREATMENT OF STRESS-RELATED AFFECTIVE DISORDERS	United States Of America	18 Aug 2003	10/524693	07 Apr 2009	7514454	18 Aug 2023	Granted	PRESTWICK PHARMACEUTICALS, INC.